Avalo Therapeutics, Inc. (AVTX) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US05338F3064
Avalo Therapeutics, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 59,000.00 USD |
| Operating income | -72.93 m USD |
| EBIT | -78.09 m USD |
| Net income | -78.26 m USD |
| Diluted EPS – continuing operations | -5.84 USD |
Full history since 2012, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Avalo Therapeutics, Inc.
Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Wayne, Pennsylvania.
More stocks
- First Bancorp, Inc /ME/ (FNLC)
- CHEMUNG FINANCIAL CORP (CHMG)
- CITIZENS FINANCIAL SERVICES INC (CZFS)
- Surya Permata Andalan Tbk PT (NATO.JK)
- Hyundai Bioscience Co. Ltd (048410.KQ)
- BlossomHill Therapeutics, Inc. Common Stock (BLSM)
- Oxiquim S.A (OXIQUIM.SN)
- Hamilton Beach Brands Holding Co (HBB)
- Infinity Capital Investments S.A. (INFINITY.RO)
- AEM (AEM.AT)
- Melcor Developments Ltd. (MRD.TO)
- Zhejiang Wufangzhai Industry Co. Ltd. A (603237.SS)
Not investment advice. All data without warranty, price as of 10.11.2026. Details in the risk notice.